Oncolytics Biotech Inc. (ONCY)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
0.54 USD
+0.05
(9.837%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 0.53 -0.01 (-0.005%) ⇩ (Oct. 14, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 3:41 a.m. EDT
The immediate outlook is sharply negative due to a relentless price collapse that has erased nearly half the company's value over the last nine years, leaving the stock trading at a fraction of its historical highs. While the recent news cycle offers a glimmer of hope with Fast Track designation for a new anal cancer therapy and promising clinical response rates, the market has clearly priced out the risk of this biotech venture. The balance sheet is fragile, with negative book value and significant operating cash burn, while the forward P/E is meaningless given the lack of earnings. Furthermore, the statistical forecasting models indicate zero directional bias for the coming month, suggesting that despite the hype, there is no immediate technical setup to catch a bounce. Without a confirmed regulatory milestone or a visible path to profitability, the current trajectory remains a deep value trap rather than a turnaround story. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.090729 |
| AutoETS | 0.091887 |
| AutoARIMA | 0.091917 |
| AutoTheta | 0.111392 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.022 |
| Excess Kurtosis | 0.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 70,569,176 |
| Forward P/E | -2.73 |
| Beta | 1.16 |
| Website | https://oncolyticsbiotech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.53846157 |
| Address1 | 4,350 Executive Drive |
| Address2 | Suite 325 |
| All Time High | 93.48 |
| All Time Low | 0.33 |
| Ask | 0.7593 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,797,570 |
| Average Daily Volume3 Month | 1,082,876 |
| Average Volume | 1,082,876 |
| Average Volume10Days | 1,797,570 |
| Beta | 1.155 |
| Bid | 0.5 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | -0.049 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5382 |
| Current Ratio | 1.353 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.56 |
| Day Low | 0.4422 |
| Display Name | Oncolytics Biotech |
| Dividend Date | 1,527,206,400 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,754,661,600 |
| Earnings Call Timestamp Start | 1,754,661,600 |
| Earnings Timestamp End | 1,794,859,200 |
| Earnings Timestamp Start | 1,794,859,200 |
| Ebitda | -37,649,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.725 |
| Enterprise Value | 64,959,152 |
| Eps Current Year | -0.3795 |
| Eps Forward | -0.1969268 |
| Eps Trailing Twelve Months | -0.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 403 283 0858 |
| Fifty Day Average | 0.747 |
| Fifty Day Average Change | -0.20879996 |
| Fifty Day Average Change Percent | -0.27951804 |
| Fifty Two Week Change Percent | -53.846157 |
| Fifty Two Week High | 1.32 |
| Fifty Two Week High Change | -0.78180003 |
| Fifty Two Week High Change Percent | -0.5922727 |
| Fifty Two Week Low | 0.44 |
| Fifty Two Week Low Change | 0.09820002 |
| Fifty Two Week Low Change Percent | 0.22318187 |
| Fifty Two Week Range | 0.44 - 1.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,002,288,600,000 |
| Float Shares | 125,050,827 |
| Forward Eps | -0.1969268 |
| Forward P E | -2.7329953 |
| Free Cashflow | -12,010,852 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | 0.050000012 |
| Fullday Change Percent | 10.204083 |
| Fullday Price | 0.5382 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.016590001 |
| Held Percent Institutions | 0.09054 |
| Implied Shares Outstanding | 131,120,719 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,527,206,400 |
| Last Split Factor | 10:95 |
| Long Business Summary | Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California. |
| Long Name | Oncolytics Biotech Inc. |
| Market | us_market |
| Market Cap | 70,569,176 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1340759 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -37,456,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 90,953,243 |
| Number Of Analyst Opinions | 6 |
| Open | 0.4979 |
| Operating Cashflow | -26,704,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Phone | 403 670 7377 |
| Post Market Change | -0.0052000284 |
| Post Market Change Percent | -0.9661888 |
| Post Market Price | 0.533 |
| Post Market Time | 1,792,022,192 |
| Previous Close | 0.49 |
| Price Eps Current Year | -1.4181819 |
| Price Hint | 4 |
| Price To Book | -10.983674 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.02 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | 0.0482 |
| Regular Market Change Percent | 9.83674 |
| Regular Market Day High | 0.56 |
| Regular Market Day Low | 0.4422 |
| Regular Market Day Range | 0.4422 - 0.56 |
| Regular Market Open | 0.4979 |
| Regular Market Previous Close | 0.49 |
| Regular Market Price | 0.5382 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 3,115,124 |
| Return On Assets | -2.11242 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 131,120,719 |
| Shares Percent Shares Out | 0.056199998 |
| Shares Short | 7,373,509 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,802,299 |
| Short Name | Oncolytics Biotech Inc. |
| Short Percent Of Float | 0.0573 |
| Short Ratio | 6.69 |
| Source Interval | 15 |
| State | CA |
| Symbol | ONCY |
| Target High Price | 5.8647966 |
| Target Low Price | 2.8514514 |
| Target Mean Price | 4.1590433 |
| Target Median Price | 4.155756 |
| Total Cash | 4,115,000 |
| Total Cash Per Share | 0.032 |
| Total Debt | 448,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.89205 |
| Two Hundred Day Average Change | -0.35385 |
| Two Hundred Day Average Change Percent | -0.39667058 |
| Type Disp | Equity |
| Volume | 3,115,124 |
| Website | https://oncolyticsbiotech.com |
| Zip | 92,121 |